Cardiovascular Science, Medicine, and Society: The Brave New World: The ACC Braunwald Lecture 2025.

Landmark clinical trials have introduced transformative therapies for lipid disorders, heart failure, and obesity, offering clinicians powerful new tools to manage increasingly complex patient populations.

具有里程碑意义的临床试验为血脂异常、心力衰竭和肥胖症引入了变革性的治疗方法，为临床医生提供了强大的新工具，以管理日益复杂的患者群体。

Discoveries in molecular medicine, including gene therapies and RNA therapeutics, have ushered in new biopharmaceutical platforms and promise the potential for curative or infrequent dosing regimens.

分子医学领域的发现，包括基因治疗和RNA治疗，已经开启了新的生物制药平台，并承诺具有治愈或减少给药方案的潜力。

Minimally invasive, percutaneous, and robotic surgical techniques, along with next-generation devices and interventional procedures, are enhancing patient outcomes and broadening access to advanced care.

微创、经皮和机器人手术技术，以及下一代设备和介入程序，正在改善患者结果并扩大对先进护理的访问。

The rapid rise of artificial intelligence and digital health technologies is reshaping how we gather, interpret, and act on data across the care continuum.

人工智能和数字健康技术的迅速发展正在改变我们在整个护理过程中收集、解读和采取行动的数据方式。

Together, these developments mark the arrival of a brave new world in cardiovascular medicine.

这些进步共同标志着心血管医学领域一个全新世界的到来。

Yet the promise of this new era is tempered by unequal access, ethical dilemmas, and potential unintended consequences at both the patient and societal levels.

然而，这一新时代的承诺因获取机会不均、伦理困境以及可能在患者和社会层面上产生的意外后果而受到限制。

This review is written in honor of Dr Eugene Braunwald, who has been a pioneer in cardiovascular science and technological innovation.

本文是为了纪念Eugene Braunwald博士而撰写的，他在心血管科学和技术革新方面是一位先驱。

The paper summarizes recent milestones in cardiovascular medicine and offers a forward-looking perspective on how to realize the full potential of innovation by translating scientific progress into equitable, responsible care and improved health outcomes.

本文总结了心血管医学领域近期的重要里程碑，并展望了如何通过将科学进步转化为公平、负责任的护理和改善健康结果，来实现创新的全部潜力。